These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35474598)

  • 21. Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring.
    Calabresi PA; Arnold DL; Sangurdekar D; Singh CM; Altincatal A; de Moor C; Engle B; Goyal J; Deykin A; Szak S; Kieseier BC; Rudick RA; Plavina T
    Mult Scler; 2021 Sep; 27(10):1497-1505. PubMed ID: 33307998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum neurofilament levels in patients with multiple sclerosis: A comparison of SIMOA and high sensitivity ELISA assays and contributing factors to ELISA levels.
    Revendova KZ; Zeman D; Bunganic R; Karasova K; Volny O; Bar M; Kusnierova P
    Mult Scler Relat Disord; 2022 Nov; 67():104177. PubMed ID: 36130459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
    Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F;
    EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
    Benkert P; Meier S; Schaedelin S; Manouchehrinia A; Yaldizli Ö; Maceski A; Oechtering J; Achtnichts L; Conen D; Derfuss T; Lalive PH; Mueller C; Müller S; Naegelin Y; Oksenberg JR; Pot C; Salmen A; Willemse E; Kockum I; Blennow K; Zetterberg H; Gobbi C; Kappos L; Wiendl H; Berger K; Sormani MP; Granziera C; Piehl F; Leppert D; Kuhle J;
    Lancet Neurol; 2022 Mar; 21(3):246-257. PubMed ID: 35182510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis.
    Rosso M; Gonzalez CT; Healy BC; Saxena S; Paul A; Bjornevik K; Kuhle J; Benkert P; Leppert D; Guttmann C; Bakshi R; Weiner HL; Chitnis T
    Ann Clin Transl Neurol; 2020 Jun; 7(6):945-955. PubMed ID: 32452160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice.
    Valentino P; Marnetto F; Martire S; Malucchi S; Bava CI; Popovic M; Bertolotto A
    Mult Scler Relat Disord; 2021 Sep; 54():103090. PubMed ID: 34182224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum neurofilament light chain correlates with myelin and axonal magnetic resonance imaging markers in multiple sclerosis.
    Yik JT; Becquart P; Gill J; Petkau J; Traboulsee A; Carruthers R; Kolind SH; Devonshire V; Sayao AL; Schabas A; Tam R; Moore GRW; Li DKB; Stukas S; Wellington C; Quandt JA; Vavasour IM; Laule C
    Mult Scler Relat Disord; 2022 Jan; 57():103366. PubMed ID: 35158472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis.
    Mariottini A; Marchi L; Innocenti C; Di Cristinzi M; Pasca M; Filippini S; Barilaro A; Mechi C; Fani A; Mazzanti B; Biagioli T; Materozzi F; Saccardi R; Massacesi L; Repice AM
    Front Neurol; 2022; 13():820256. PubMed ID: 35280289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal serum neurofilament light chain (sNfL) concentration relates to cognitive function in multiple sclerosis patients.
    Mattioli F; Bellomi F; Stampatori C; Mariotto S; Ferrari S; Monaco S; Mancinelli C; Capra R
    J Neurol; 2020 Aug; 267(8):2245-2251. PubMed ID: 32296939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis.
    Maggi P; Kuhle J; Schädelin S; van der Meer F; Weigel M; Galbusera R; Mathias A; Lu PJ; Rahmanzadeh R; Benkert P; La Rosa F; Bach Cuadra M; Sati P; Théaudin M; Pot C; van Pesch V; Leppert D; Stadelmann C; Kappos L; Du Pasquier R; Reich DS; Absinta M; Granziera C
    Neurology; 2021 Aug; 97(6):e543-e553. PubMed ID: 34088875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis.
    Rosso M; Healy BC; Saxena S; Paul A; Bjornevik K; Kuhle J; Benkert P; Leppert D; Guttmann C; Bakshi R; Weiner HL; Chitnis T
    J Neuroimaging; 2021 Mar; 31(2):388-393. PubMed ID: 33476489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.
    Tavazzi E; Bergsland N; Kuhle J; Jakimovski D; Ramanathan M; Maceski AM; Tomic D; Hagemeier J; Kropshofer H; Leppert D; Dwyer MG; Weinstock-Guttman B; Benedict RHB; Zivadinov R
    J Neurol; 2020 Mar; 267(3):802-811. PubMed ID: 31768628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Disanto G; Barro C; Benkert P; Naegelin Y; Schädelin S; Giardiello A; Zecca C; Blennow K; Zetterberg H; Leppert D; Kappos L; Gobbi C; Kuhle J;
    Ann Neurol; 2017 Jun; 81(6):857-870. PubMed ID: 28512753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum Neurofilament Light Chain Concentration Correlates with Infarct Volume but Not Prognosis in Acute Ischemic Stroke.
    Onatsu J; Vanninen R; Jäkälä P; Mustonen P; Pulkki K; Korhonen M; Hedman M; Zetterberg H; Blennow K; Höglund K; Herukka SK; Taina M
    J Stroke Cerebrovasc Dis; 2019 Aug; 28(8):2242-2249. PubMed ID: 31151840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
    Monreal E; Fernández-Velasco JI; García-Sánchez MI; Sainz de la Maza S; Llufriu S; Álvarez-Lafuente R; Casanova B; Comabella M; Ramió-Torrentà L; Martínez-Rodríguez JE; Brieva L; Saiz A; Eichau S; Cabrera-Maqueda JM; Villarrubia N; Espiño M; Pérez-Miralles F; Montalbán X; Tintoré M; Quiroga-Varela A; Domínguez-Mozo MI; Rodríguez-Jorge F; Chico-García JL; Lourido D; Álvarez-Cermeño JC; Masjuan J; Costa-Frossard L; Villar LM
    JAMA Neurol; 2023 Apr; 80(4):397-403. PubMed ID: 36848127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors influencing serum neurofilament light chain levels in normal aging.
    Koini M; Pirpamer L; Hofer E; Buchmann A; Pinter D; Ropele S; Enzinger C; Benkert P; Leppert D; Kuhle J; Schmidt R; Khalil M
    Aging (Albany NY); 2021 Dec; 13(24):25729-25738. PubMed ID: 34923481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis.
    McComb M; Krikheli M; Uher T; Browne RW; Srpova B; Oechtering J; Maceski AM; Tyblova M; Jakimovski D; Ramasamy DP; Bergsland N; Krasensky J; Noskova L; Fialova L; Weinstock-Guttman B; Havrdova EK; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M
    J Clin Lipidol; 2020; 14(5):675-684.e2. PubMed ID: 32758395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum neurofilament light chain: No clear relation to cognition and neuropsychiatric symptoms in stable MS.
    Aktas O; Renner A; Huss A; Filser M; Baetge S; Stute N; Gasis M; Lepka K; Goebels N; Senel M; Graf J; Enzinger C; Pinter D; Antoch G; Turowski B; Hartung HP; Albrecht P; Otto M; Tumani H; Penner IK
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32972970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroaxonal and Glial Markers in Patients of the Same Age With Multiple Sclerosis.
    Loonstra FC; de Ruiter LRJ; Koel-Simmelink MJA; Schoonheim MM; Strijbis EMM; Moraal B; Barkhof F; Uitdehaag BMJ; Teunissen C; Killestein J
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36543540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
    Uher T; McComb M; Galkin S; Srpova B; Oechtering J; Barro C; Tyblova M; Bergsland N; Krasensky J; Dwyer M; Havrdova EK; Posova H; Vaneckova M; Zivadinov R; Horakova D; Kuhle J; Ramanathan M
    Mult Scler; 2021 Feb; 27(2):220-231. PubMed ID: 32255388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.